Landos Biopharma, Inc.
LABP · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $134,085 | $22,720 | $24,086 | $26,134 |
| - Cash | $29,054 | $37,549 | $42,408 | $44,049 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $105,031 | -$14,829 | -$18,322 | -$17,915 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$9,252 | -$5,561 | -$5,199 | -$4,399 |
| % Margin | – | – | – | – |
| Net Income | -$8,897 | -$6,119 | -$5,860 | -$3,922 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.43 | -0.99 | -0.94 | -0.63 |
| % Growth | -44.4% | -5.3% | -49.2% | – |
| Operating Cash Flow | -$8,498 | -$4,969 | -$2,228 | -$5,110 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$8,498 | -$4,969 | -$2,228 | -$5,110 |